Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine
Key facts
- Who runs it
- Theis S. Itenov
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- NCT07273071
- EU 2026-525895-25-00
- U1111-1336-2257
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 360 people, planned
- Started
- 7 Sept 2026
- Expected to end
- Jul 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- N-Acetylcysteine (NAC) Treatment
- Record updated
- 16 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age ≥18 years
- Documented clinical suspicion of infection
- Model for end-stage liver disease (MELD) score ≥9
Who cannot take part
- Any previous severe anaphylaxis
- Ongoing treatment with N-acetylcysteine at randomization
- Ongoing treatment with nitroglycerin
- Other known allergy to N-acetylcysteine
- Involuntary admission under the psychiatric law
- Any other condition deemed by the investigator to compromise patient safety or trial integrity (e.g., severe coagulopathy, uncontrolled bleeding, diabetic ketoacidosis)
- Admitted to hospital >24 hours before randomization
- Documented clinical suspicion of bile duct obstruction
- Refractory circulatory shock
- Informed consent not obtainable
- Inability to read and understand Danish to a degree that allows valid informed consent and completion of trial assessments
- Expected initiation of palliative care within 48 hours of randomization
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of the IMPACT-NAC trial is to assess the effects of N-acetylcysteine on survival and hospital length of stay in adults admitted to the emergency department with acute infection or sepsis and evidence of liver dysfunction.
Read full original descriptionShow less
The main question it aims to answer is: does N-acetylcysteine increase the number of days alive and out of the hospital within the first 14 days after enrolment in the trial?
To answer this question, we will conduct a randomized, double-blinded controlled trial of 360 participants.
Participants will be randomized to either N-acetylcysteine or placebo (normal saline without active drugs). This will be administered as an infusion during four hours within the first day of hospital admission.
The 2 groups in the trial
- N-acetylcysteineTreatment being tested
Treatment: N-Acetylcysteine (NAC) Treatment
- Placebo (normal saline)No study treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomized, Placebo-controlled, Blinded, Parallel-group Clinical Trial to Assess the Efficacy of N-acetylcysteine in Adults With Acute Infections or Sepsis and Evidence of Liver Dysfunction: the IMPACT-NAC Trial
- Record updated
- 16 September 2026